Business Wire

Nike and NBA Introduce New Statement Edition Uniform, First On-Court Hooded Jacket and the First NBA Connected Jersey, the Future of Fan Apparel

Share

Ushering in a radical evolution of the fan experience, NIKE, Inc. (NYSE:NKE) and the NBA today unveiled three new innovations: the Nike NBA Connected Jersey, the first NBA jersey that gives the wearer an all-access pass into the world of their favorite team and players; Statement Edition uniforms; and the Nike Therma Flex Showtime Warm-up Jacket, the first hooded jacket to be worn on the court during gametime. The official announcements took place at an event in Los Angeles attended by players from all 30 NBA teams.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170915005965/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Using New NikeConnect Technology, Retail Jerseys Will Unlock Exclusive Experiences and Customized Content for Fans' Favorite Teams and Players (Photo: Business Wire)

“When you think about basketball, you think of Nike and the NBA,” said Mark Parker, Chairman, CEO and President of NIKE, Inc. “After helping fuel the sport’s impact for years, we are thrilled to now be able to push the boundaries of what’s possible directly with the NBA. From modernizing the look of the game to revolutionizing how fans can be a part of it, we can’t wait for the season to start.”

“Our Nike uniforms set a new standard for connecting our most passionate fans with their favorite NBA teams and players,” said Adam Silver, NBA Commissioner. “Nike has once again taken the game of basketball to a new level, this time with one of the most advanced jerseys in sports.”

Using new NikeConnect technology, each adult-sized Nike NBA Connected Jersey will have an embedded NFC (near field communication) chip that will launch real-time team and player content such as pregame arrival footage, highlight packages and top players’ favorite music playlists – all on the jersey owner’s mobile device. Throughout the season, a wealth of exclusive offers and experiences will bring fans closer to the game they love.

To unlock it all, fans will download the NikeConnect app and tap the jersey with their smartphone. These jerseys become available online globally on Sept. 29, rewarding the game’s fans with a revolutionary experience that creates a new point of connection between fans and the game.

“In our new connected era, Nike will lead with products that build a relationship with our consumers,” said Trevor Edwards, President, Nike Brand. “With NikeConnect, we deliver to basketball fans everywhere the personal and premium experiences we know they love.”

Nike and the NBA also unveiled the third of four core team uniforms – the Statement Edition, inspired by teams’ desire to make a bold statement the moment they step on the court. Nike’s designers worked with the teams and the brand’s roster of athletes to create new and updated uniforms for this third edition.

The Statement Edition uniform follows the earlier unveiling of the Association and Icon Edition uniforms. As previously announced, the home teams will determine which uniforms to wear at their games. The fourth team edition will be released later this year.

In addition to the new uniforms, Nike and the NBA debuted the Nike Therma Flex Showtime Warm-up Jacket, the first on-court warm-up jacket with a performance hood. Celebrating the style of the game, Nike designers refreshed a beloved apparel staple into a new performance product for athletes on and off the court.

The jacket, created with new Nike Therma Flex fabric, helps athletes maintain the right body temperature during pregame warm-ups and downtime during a game – a critical element for peak performance. Developed with input from top NBA athletes, the reimagined hood allows for optimal vision, hearing and warmth, delivering a greater intersection between performance and style – a key request from NBA athletes.

The Nike NBA Connected Jersey is available exclusively online starting Sept. 29, and the Nike NBA uniforms and Nike Therma Flex Showtime Warm-up Jacket will debut on court on Sept. 30, the start of the NBA preseason. All Statement Edition jerseys will be available at retail on Nov. 20, and will begin being worn on-court on Nov. 25.

About the NBA

The NBA is a global sports and media business built around three professional sports leagues: the National Basketball Association, the Women’s National Basketball Association and the NBA G League. The league has established a major international presence with games and programming in 215 countries and territories in 49 languages, and NBA merchandise for sale in more than 125,000 stores in 100 countries on 6 continents. NBA rosters at the start of the 2016-2017 season featured a record 113 international players from 41 countries and territories. NBA Digital’s assets include NBA TV, NBA.com, NBA App and NBA LEAGUE PASS. The NBA has created one of the largest social media communities in the world, with more than 1.3 billion likes and followers globally across all league, team and player platforms. Through NBA Cares, the league addresses important social issues by working with internationally recognized youth-serving organizations that support education, youth and family development and health-related causes.

About NIKE, Inc.

NIKE, Inc., based near Beaverton, Ore., is the world's leading designer, marketer and distributor of authentic athletic footwear, apparel, equipment and accessories for a wide variety of sports and fitness activities. Wholly-owned NIKE, Inc. subsidiary brands include Converse, which designs, markets and distributes athletic lifestyle footwear, apparel and accessories; and Hurley, which designs, markets and distributes surf and youth lifestyle footwear, apparel and accessories. For more information, NIKE, Inc.’s earnings releases and other financial information are available at http://investors.nike.com. Individuals can also visit http://news.nike.com/ and follow @Nike.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nike Media Contact:
Nike Media Relations, 212-367-4447
Media.Relations@nike.com
or
NBA Media Contact:
Amanda Thorn, 914-282-0257
athorn@nba.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th

WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release

Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release

Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye